Search - tctmd.com

Displaying 1 - 20 of 49

Sort: Relevancy | Date

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

News Conference News ESC Heart Failure 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

May 20, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

News Conference News THT 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

February 19, 2025

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

November 14, 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

Transcatheter Edge-to-Edge Repair Shows Benefit in Moderate MR

News Conference News NY Valves 2024

Transcatheter Edge-to-Edge Repair Shows Benefit in Moderate MR

Michael O'Riordan

June 10, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Five-Year Follow-up Reassures on Severe Patient-Prosthesis Mismatch in TAVI

News Conference News TVT 2023

Five-Year Follow-up Reassures on Severe Patient-Prosthesis Mismatch in TAVI

June 14, 2023

‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients

News Conference News TVT 2023

‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients

Michael O'Riordan

June 09, 2023

TEER or VAD/Transplant in the Advanced HF Patient With MR?

News Conference News THT 2023

TEER or VAD/Transplant in the Advanced HF Patient With MR?

March 20, 2023

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

News Conference News PCR London Valves 2022

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

December 07, 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

News Conference News AHA 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

November 11, 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

News Conference News TCT 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

Michael O'Riordan

September 22, 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

News Conference News TCT 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

Michael O'Riordan

September 17, 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

September 16, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.